The iconic rise of Viagra has consistently remained a example of pharmaceutical success, but its legacy within the broader sector now raises questions about potential yields . Alternative versions are eroding exclusivity , causing worries that investing in companies closely tied to Viagra's once-dominant position could be a dangerous decision , esp